Onco Actu du 3 décembre 2018

	1. Biologie
The long and short of CDK12 [MIT News] A new study linking RNA processing to DNA repair may open new avenues to cancer therapy.
	1.4 Biologie - Technos
Genetically Modified People Are Walking Among Us [NY Times] And, so far, they’re just fine. America needs a sober debate about the pros and cons of Crispr instead of a paranoid ban on the technology.
	3.4 Chimioprévention
Why high risk women are reluctant to take breast cancer drug [University of Leeds] The study was funded by Cancer Research UK and published in the journal Clinical Breast Cancer.
Women reveal reasons they reject a preventive treatment for breast cancer [Cancer Research UK] The researchers, led by a team from the University of Leeds, asked more than 400 healthy women at a higher-risk of breast cancer, from 20 centres across England, whether they thought they needed to take tamoxifen and their concerns about medication.
	4.12 Biopsies liquides
Blood test could predict if chemotherapy will work for advanced prostate cancer patients [Garvan Institute] Patients with metastatic, castration-resistant prostate cancer (mCRPC) were assessed using a blood test to detect the presence of a methylated copy of the glutathione s transferase gene (mGSTP1). The mGSTP1 biomarker was detected in the blood of 81% of patients before treatment.
	4.2 Dép., diag. & prono. - Génome
Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery [NCI] To try to address the rise in diagnostic thyroid surgeries, Dr. Nikiforov and his colleagues developed the ThyroSeq Genomic Classifier test. The test measures changes in 112 genes that have been linked to thyroid cancer. These changes include mutations, gene fusions, changes in copy number, and alterations in gene expression.
	5. Traitements
Blasting radiation therapy into the future: New systems may improve cancer treatment [Stanford Medicine] Stanford University and SLAC National Accelerator Laboratory are teaming up to develop a faster and more precise way to deliver X-rays or protons, quickly zapping cancer cells before their surrounding organs can move. This will likely reduce treatment side effects by minimizing damage to healthy tissue.
	5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma [Celgene] KarMMa is a pivotal, open-label, single-arm, multi-center phase 2 study evaluating the efficacy and safety of bb2121 in patients with relapsed and refractory multiple myeloma. In November 2017, bb2121 was granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration and PRIority Medicines (PRIME) eligibility by the European Medicines Agency.
	5.12.3 Immunothérapies-combinaisons
CRI study highlights CTLA-4’s marquee role in PD-1/L1 combos — despite an increasingly troubled clinical profile [EndPoints] Looking at 533 PD-1/L1 studies, the researchers found that while the trials are attracting patient recruits faster than other types of oncology drugs, the number of patients recruited per site has dropped from 1.15 per site per month four years ago to 0.35 patients per site per month in 2018.
	5.12.8 Immunothérapies - Economie
BMS flips negative NICE ruling on Opdivo, winning thumbs-up for preventing melanoma relapse [FiercePharma] The drug will only be covered by England’s Cancer Drugs Fund (CDF) for the next two years. To gain full coverage via the National Health Service after that, BMS will have to present further data comparing Opdivo with Yervoy and routine surveillance. That means Opdivo will be subject to NICE’s scrutiny yet again.
	5.2.1 Pharma - Partenariats
Dutch firm argenx, J&J affiliate to collaborate on cancer therapy [Reuters] The deal, which is potentially worth up to $1.6 billion, represents a global collaboration and licensing agreement for the cancer drug Cusatuzumab.
	5.2.2 Pharma - Fusions & Acquisitions
GSK buys cancer biotech Tesaro for $5.1B [STAT] Tesaro, based in Waltham, Ma., sells a drug called Zejula for ovarian cancer. Chatter about the company seeking a sale has swirled repeatedly over the past year, most recently resurfacing last month and sending its stock price higher.
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company [GSK] TESARO is a commercial-stage biopharmaceutical company, with a major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer.
	5.2.3 Pharma - économie
Prepping for key ASH presentation, little Aprea Therapeutics gets $57M to fuel PhIII p53 cancer study [EndPoints] Today the biotech touted a $57 million raise for a drug designed to correct mutant p53 so it can go about its business in killing cells.
	5.8.7 ASH - Lymphomes
Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma [Roche] Polatuzumab vedotin in combination with MabThera/Rituxan (rituximab) plus bendamustine more than doubled overall survival, compared to MabThera/Rituxan plus bendamustine alone in the phase Ib/II GO29365 study.
	6. Lutte contre les cancers
Proton beam failure leaves hundreds of child cancer patients at risk [The Telegraph] NHS officials have admitted that no patient has yet received state-of-the-art proton beam therapy (PBT) at either its new London or Manchester sites, despite a Government pledge to be treating 1,500 a year by 2018.
	6.4 Médico-éco
Can better cancer care lower company's health costs? [Reuters] Activision Blizzard, an entertainment company that employs more than 6,000 people in the United States, has been spending less on healthcare than projected for the last few years, in large part because it is offering better options for cancer care.